Effect of Infraclavicular and Interscalen Block on Oxygenitaon of the Forearm
NCT ID: NCT04748211
Last Updated: 2021-02-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
104 participants
INTERVENTIONAL
2018-06-15
2019-06-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Core Stabilization Approach on Patients With Upper Extremity Injuries
NCT01659112
Effects Of Unilateral Forearm Vibration On The Loss Of Muscle And Bone Of Contralateral Forearm
NCT01553487
Investigation of Physical Activity and Associated Factors in Lower Extremity Amputees
NCT03825432
The Effectiveness of Cross-training on an Immobilised Forearm
NCT06562218
A Comparative Study Between Infraclavicular and Axillary Blocks for Assessment of Motor Power Using Handgrip Dynamometer
NCT05325372
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Infraclavicular Block
Group I received USG and neurostimulator guided infraclavicular block, 10 ml 2% lidocain and 10 ml 0.05% marcaine was administered for local anetshesia. After the block was administered MAP, HR, TAV, BAD, BAA, BF, PI and rSO 2 values were measured and recorded at the 10th, 20th, and 30th minutes.
Infraclavicular Block
USI and neurostimulator guided infraclavicular block, 10 ml 2% lidocain and 10 ml 0.05% marcaine was administered for local anetshesia. After the block was administered MAP, HR, TAV, BAD, BAA, BF, PI and rSO 2 values were measured and recorded at the 10th, 20th, and 30th minutes.
Interscalen Block
Group II received USG and neurostimulator guided interscalen block. 10 ml 2% lidocain and 10 ml 0.05% marcaine was administered for local anetshesia. After the block was administered MAP, HR, TAV, BAD, BAA, BF, PI and rSO 2 values were measured and recorded at the 10th, 20th, and 30th minutes.
Interscalen Block
USI and neurostimulator guided interscalen block, 10 ml 2% lidocain and 10 ml 0.05% marcaine was administered for local anetshesia. After the block was administered MAP, HR, TAV, BAD, BAA, BF, PI and rSO 2 values were measured and recorded at the 10th, 20th, and 30th minutes.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Infraclavicular Block
USI and neurostimulator guided infraclavicular block, 10 ml 2% lidocain and 10 ml 0.05% marcaine was administered for local anetshesia. After the block was administered MAP, HR, TAV, BAD, BAA, BF, PI and rSO 2 values were measured and recorded at the 10th, 20th, and 30th minutes.
Interscalen Block
USI and neurostimulator guided interscalen block, 10 ml 2% lidocain and 10 ml 0.05% marcaine was administered for local anetshesia. After the block was administered MAP, HR, TAV, BAD, BAA, BF, PI and rSO 2 values were measured and recorded at the 10th, 20th, and 30th minutes.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ASA Score I-III
* undergoing elective or emergency arm, elbow and forearm surgery
Exclusion Criteria
* Patients who had any neurological disorders preventing the evaluation of the sensory block in the upper extremity,
* Infection in the area to be blocked with ICB or ISB,
* Non-cooperated patients
* Patients with coagulopathy,
* Morbidly obese patients
* Patients with diabetes mellitus
* Patients with hypertension
* Patients with peripheral artery disease
* Patients with allergy to the drugsto be used
* Patients who had trauma in the area scheduled for the block
* Paitens who had deterioration of anatomical integrity because of previous surgery
* Pregnant women
* Patients whose block failed
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bulent Ecevit University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
OZCAN PISKIN, MD
associate professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Eren Açıkgöz, M.D.
Role: PRINCIPAL_INVESTIGATOR
Bulent Ecevit University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Zonguldak Bulent Ecevit University
Zonguldak, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2017-116-06/12
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.